Hearing that treatment should begin before surgery can feel confusing. If you have breast cancer, you may wonder why your doctors aren’t removing the tumour first. The order has a purpose: treatment before surgery may shrink the cancer and show how it responds to medicine, while surgery remains part of the plan for many patients.
The right sequence depends on your cancer’s stage and subtype, test results, overall health and circumstances. Understanding what each step could change can help you discuss the recommendation with your specialist team.
Quick Answer
Neoadjuvant breast cancer treatment means giving medicine before surgery. It may include chemotherapy, HER2-targeted drugs, immunotherapy or hormone-blocking treatment, depending on the tumour. Your team may recommend it to reduce a tumour’s size, assess its response or guide decisions after surgery. Shrinkage isn’t guaranteed, and a scan that no longer shows cancer usually doesn’t remove the need for an operation.
5 Key Takeaways
- Neoadjuvant treatment comes before surgery; adjuvant treatment comes afterward.
- Your stage, biopsy results and tumour subtype help determine whether treatment should start before an operation.
- A smaller tumour may make breast-conserving surgery possible, but it won’t do so for everyone.
- Your team checks your response during treatment and reviews the tissue removed at surgery.
- You can ask about the timetable, side effects, costs and a second opinion before agreeing to a plan.
Why neoadjuvant breast cancer treatment comes first
Medicine given before surgery travels through the body and acts on cancer cells. If it reduces a tumour in the breast, your surgeon may have more options for removing it. The response also gives your team information about how well that particular cancer reacts to the medicines.
The ASCO overview of preoperative treatment describes its role for selected patients, particularly those with higher-risk HER2-positive or triple-negative disease. That doesn’t mean every breast cancer needs this approach.
How it differs from treatment after surgery
With adjuvant therapy, surgery happens first. Medicines given afterward aim to reduce the risk that cancer cells left elsewhere in the body will cause problems later. Some treatments, including radiotherapy or hormone therapy, may also follow surgery after a neoadjuvant course.
Giving similar medicines before rather than after surgery doesn’t automatically improve overall survival. The timing is useful when shrinking the cancer or seeing its response could affect later decisions.
When surgery first may make more sense
A small tumour that surgeons can remove readily may not need preoperative treatment. Your doctor also considers lymph nodes, other illnesses, previous treatments and what you want from surgery. If cancer has spread to distant organs, the goals and role of surgery can differ substantially.
Ask your team what they expect to learn or achieve by starting with medicine in your case.
How your cancer subtype shapes the medicines
A biopsy confirms the diagnosis and lets the pathology laboratory test for hormone receptors and HER2. These results matter because cancers that look similar on a scan can respond differently to the same drug. Doctors also consider tumour size, lymph-node findings and whether a treatment is available and suitable for you.
HER2-positive and triple-negative breast cancer
For certain higher-risk HER2-positive cancers, treatment before surgery may combine chemotherapy with HER2-targeted medicines such as trastuzumab and pertuzumab. For eligible triple-negative breast cancer, a chemotherapy plan may include a taxane, carboplatin and an anthracycline-based combination. Some patients may also be offered immunotherapy, such as pembrolizumab, after specialist assessment.
These are examples, not a prescription. The ASCO neoadjuvant breast cancer guideline ties treatment choices to subtype and risk. Your oncologist should explain the expected benefit, possible side effects and whether a medicine is accessible through your hospital or funding arrangement.
Hormone receptor-positive, HER2-negative disease
Some hormone receptor-positive cancers can be treated before surgery with hormone-blocking medicine. An aromatase inhibitor may suit a postmenopausal patient when the aim is to reduce the tumour before an operation. Other patients may be advised to have chemotherapy or surgery first.
Menopausal status, tumour behaviour and your wider treatment plan affect that choice. Ask whether genetic testing or another test would change the recommendation, rather than assuming every available test is necessary.
What happens between diagnosis and surgery
Neoadjuvant breast cancer treatment usually follows a sequence of assessment, treatment cycles and review. The number of visits and the time before surgery vary by regimen and by how you tolerate it. Your oncology team should give you an expected timetable and explain what might cause it to change.
Establishing a starting point
Before treatment, your team reviews the biopsy and pathology report, scans and examination findings. Imaging may include an ultrasound, mammogram or MRI. Tests to assess possible spread depend on your stage and symptoms; you won’t necessarily need every scan.
If an area in the breast or a lymph node is likely to shrink, your team may discuss placing a small marker at the biopsied site. This can help surgeons locate the original area later. Ask which findings establish your stage and whether any result remains uncertain.
Checking whether treatment is working
At follow-up visits, your clinician may examine the breast and lymph nodes, ask about symptoms and arrange imaging when useful. The team also checks side effects and blood results so it can decide whether treatment remains safe and appropriate.
A lump that feels smaller is encouraging, but it doesn’t prove every cancer cell has gone. Likewise, an MRI or ultrasound can help show a response without confirming a complete one. If the tumour isn’t responding as expected, the specialists review whether to continue, change treatment or bring surgery forward.
The team managing your care may include an oncologist, breast surgeon, radiologist and pathologist. Keep your appointment schedule and tell them promptly about new symptoms or troublesome side effects.
How treatment may change your surgery options
A response before surgery can alter what’s possible, but the final operation still depends on where the cancer began and what remains. Your breast surgeon should review the options with you after treatment, using the full set of findings.
Breast-conserving surgery or mastectomy
Breast-conserving surgery, often called a lumpectomy, removes the cancerous area with a rim of tissue. If a tumour shrinks enough, this may become an option where mastectomy was initially expected. Radiotherapy commonly follows breast-conserving surgery.
Some people still need or prefer a mastectomy. Reasons can include cancer in more than one area, the extent of the original disease, difficulty obtaining clear margins, genetic risk or personal preference. This doesn’t automatically mean you can avoid radiotherapy.
Even if imaging shows no visible tumour, your surgeon still needs to address the original cancer site; imaging can’t reliably prove that no cancer cells remain.
What happens to the lymph nodes
If cancer was found in underarm nodes, preoperative treatment may also reduce disease there. For some patients, the response can affect whether a sentinel lymph node biopsy, which checks selected first-draining nodes, is appropriate or whether more extensive node surgery is needed.
This requires careful planning. The team considers whether nodes were cancer-positive before treatment, how they responded and what they find at surgery. Treatment before surgery doesn’t guarantee fewer nodes removed. Ask your surgeon which node procedure they expect and what findings could change it.
What a pathologic complete response means
After surgery, a pathologist examines the removed breast tissue and sampled nodes. A pathologic complete response, or pCR, generally means they find no remaining invasive cancer in those areas. Definitions can differ in how they account for non-invasive disease, so ask your doctor what your report says.
A pCR is good news, particularly for some aggressive subtypes, and can help guide treatment afterward. It isn’t a guarantee of cure. If cancer remains, that information may also help your oncologist decide what to recommend next. Further medicine, radiotherapy or follow-up may still be needed.
Your team can’t confirm pCR from how a lump feels or from an imaging result alone. If you’re told your scans look clear, ask what will only become known after surgery.
Planning treatment and costs in Malaysia
Treatment decisions need to fit your medical needs and practical situation. In Malaysia, medicine access, appointment timing and charges can differ between public and private care, and between hospitals. Ask for a written plan before making financial or travel arrangements.
Questions to take to your oncology appointment
Bring a family member or write down the answers if that helps you remember them. Useful questions include:
- What stage and subtype do my biopsy, scans and lymph-node tests show?
- Why do you recommend treatment before surgery rather than surgery first?
- Which medicines are planned, how long might treatment take, and how will you check the response?
- What side effects need an urgent call, and who should I contact?
- How could the results change my breast surgery, lymph-node surgery or treatment afterward?
- What is the estimated cancer treatment cost, including drugs, scans, surgery and follow-up, and what might insurance or available funding cover?
Ask for an itemised estimate if you’re paying privately. Your team can also explain which parts of the plan are confirmed and which depend on your response.
Getting another specialist perspective
If the proposed sequence or operation is difficult to understand, a cancer treatment second opinion can help you review it. Another qualified specialist may confirm the existing plan, clarify a result, suggest further assessment or discuss a medically suitable approach. A different opinion doesn’t mean your first doctor was wrong or that another treatment will be better.
For a medical second opinion, gather your pathology report, receptor results, scan reports, images if available, current medicine list and proposed treatment plan. Explore Medical Report Review Support is a resource for coordinating information for review; your treating specialists remain responsible for medical interpretation and decisions.
If you need help arranging another specialist perspective, Explore Cancer Second Opinion Support offers coordination support rather than a medical opinion from the service itself. Tell your current team if you’re seeking a review so you can ask what timing is safe.
Frequently Asked Questions
Will chemotherapy before surgery always shrink my tumour?
No. Some cancers respond strongly, while others shrink less than expected. Your oncologist monitors your progress and can review the plan if the response is limited or side effects become difficult.
Can I skip surgery if scans show no cancer?
Usually, no. Scans cannot reliably rule out microscopic cancer. Surgery allows the team to remove and examine tissue from the original tumour area, even when imaging looks clear.
Is treatment before surgery right for a small HER2-positive cancer?
Not necessarily. Size and lymph-node status matter. ASCO’s guidance for small HER2-positive tumours says preoperative chemotherapy and HER2-targeted medicines shouldn’t routinely be offered for certain very small, node-negative cancers. Your specialist can explain how that applies to your results.
Does a complete response mean I won’t need more treatment?
Not always. A pCR is determined after surgery, and your team may still recommend further treatment based on the original cancer, operation and overall plan. Ask which decisions depend on the surgical pathology report.
A clearer next step
Treatment before surgery can give your team a chance to reduce the cancer and assess its response. Your own test results determine whether that opportunity outweighs the reasons to operate first. Ask what the proposed sequence could change, then revisit the surgical plan with your team as results come in.
This content is for general educational purposes only. It may not apply to every patient and is not medical advice, a diagnosis or a treatment recommendation. Consult your own doctor, oncologist or qualified healthcare professional before making medical decisions.
